AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 OCT 9 - (NewsRx.com & NewsRx.net) -- MedImmune, Inc., (MEDI) announced that it has completed the submission of information requested by the U.S. Food and Drug Administration (FDA) for FluMist (influenza virus vaccine live, intranasal), a live attenuated influenza vaccine delivered as a nasal mist, currently under FDA review.
The information submitted over the last several weeks was in direct response to questions raised by the FDA in a complete response letter issued on July 10, 2002. The Biologics License ...